The News Review:

- Patient privacy rules hamper US research
- University of California San Francisco Diabetes Center Calif.
- Vince and Associates Clinical Research Partners with Private Equity…
- Clinipace Finalist in NCTA Tech Awards: Winners Announced Thursday
- Volunteers to find out who got real AIDS vaccine
- HIPAA slows cures: survey
- Grant Will Fund Research Aimed At Genetically Engineering The Human…

Patient privacy rules hamper US research
Nature.com – Nature.com (subscription) – Nov 14, 2007
For more controversial topics we reserve the right to moderate before comments are published. WHY I N LNGER D CLINICAL RESEARCH. Professor emeritus Johns Hopkins Medical Institutions BaltimoreBully for Dr.

University of California San Francisco Diabetes Center Calif.
ABC News – Nov 14, 2007
ur physicians and nurses actively pursue research and teaching while maintaining the highest standards of clinical care. Most will argue that it is in fact our strong commitment to clinical research that has kept the Diabetes Clinical Center ranked as one of the top centers in the nation for diabetes care. ur active clinical research program means that our patients have early access to the late-breaking technologies new treatment options and new strategies for diagnosing and managing type 1 and type 2 diabetes.

Vince and Associates Clinical Research Partners with Private Equity…
Free with registration – Business Wire – AccessMyLibrary.com – Nov 14, 2007
–>CPYRIGHT 2007 Business Wire VERLAND PARK Kan. — Vince and Associates Clinical Research (VNA) a leading independent provider of clinical trial services to the global pharmaceutical and biotechnology industry announced today it has partnered with private equity investor Celerity Partners (Celerity). This partnership will enable Vince and Associates to strategically expand its leading market presence throughout the.

Clinipace Finalist in NCTA Tech Awards: Winners Announced Thursday
carolinanewswire.com – Nov 14, 2007
Clinipace recent recipient of the 2007 Triangle Business Journal’s “Best Places to Work” award has been receiving a good deal of accolades this year due to its progressive approach to the clinical research software market. Clinipace just in its third full year of operations is making headway in the market by providing a more efficient single-platform clinical workflow engine that eliminates unnecessary infrastructure such as other clinical systems and in some cases service providers. Clinipace’s innovative workflow approach not only enables its clients to address the very specific needs of their research project but it enables Clinipace to run a more efficient operation — savings that Clinipace passes on to their customers. Clinipace believes this efficiency has opened up new markets that have been underserved in the past… About Clinipace Clinipace is a clinical research software company providing a single integrated data capture and study management platform for post-approval research and registries conducted by biopharmaceutical and medical device companies Clinical Research rganizations (CRs) and Academic Medical Centers (AMCs). ur platform called Tempo is delivered via a web-based on-demand architecture that streamlines the clinical research process by eliminating the integration headaches associated with multiple platforms reducing project efforts and costs from startup to conclusion and empowering project stakeholders to make informed real-time decisions regarding their research. For more information on Clinipace please visit:.

Volunteers to find out who got real AIDS vaccine
CTV.ca – Nov 14, 2007
It’s still unclear why more of the vaccinated volunteers wound up getting HIV than those who got the placeboes. Keith Gottesdiener vice president of clinical research at Merck Research Laboratories said one possibility is that the vaccine could have somehow made people more susceptible to HIV infection. It’s also possible that the higher numbers were simply coincidence. Merck’s head of medical affairs for vaccines Mark Feinberg said it could be a few years before further investigation and results of other drugmakers’ vaccine tests clear up the mystery.

HIPAA slows cures: survey
pittsburghlive.com – Nov 14, 2007
Two-thirds said HIPAA made research “a great deal” more difficult. The findings are being published today in the Journal of the American Medical Association. “HIPAA appears to be slowing the progress of clinical research by adding time and cost and potentially eliminating some new study (ideas)” Dr. Roberta Ness the author said in an e-mail from India where she is working on an unrelated public health project. story continues belowThe HIPAA Privacy Rule was enacted in 2003 with the goal of balancing patient privacy with the legitimate use of patient information for social good such as preventing or treating diseases. It created additional hurdles to obtaining patient data for research projects however. “Let’s say you have inoperable lung cancer and the doctors are giving you two years to live.

Grant Will Fund Research Aimed At Genetically Engineering The Human…
Medical News Today – Medical News Today (press release) – Nov 14, 2007
Keck Foundation to fund collaborative research to genetically engineer the human immune system so it can fight melanoma. The project brings together top experts in basic science tumor immunology molecular imaging embryonic stem cell biology gene medicine and clinical research from UCLA the California Institute for Technology Children’s Hospital Los Angeles and the University of Southern California. Leading-edge technology will be used to bolster the immune system through genetic engineering and observe in real time using positron emission tomography (PET) as the immune system recognizes attacks and kills the cancer. “Something like this has never been done before” said Dr. James Economou deputy director of the Jonsson Cancer Center and the study’s principal investigator. “We are writing one of the most exciting stories in human biology the genetic engineering of the human immune system.